

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

ETAS ID: TM452580

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	RELEASE OF SECURITY INTEREST		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
U.S. BANK NATIONAL ASSOCIATION		11/20/2017	National Banking Association:
RECEIVING PARTY DATA			
Name:	SUPERNUS PHARMACEUTICALS, INC.		
Street Address:	1550 EAST GUDE DRIVE		
City:	ROCKVILLE		
State/Country:	MARYLAND		
Postal Code:	20850		
Entity Type:	Corporation: DELAWARE		
PROPERTY NUMBERS Total: 9			
Property Type	Number	Word Mark	
Registration Number:	2410482	MICROTROL	
Registration Number:	2505388	OPTISCREEN	
Registration Number:	4441262	OXTELLAR XR	
Registration Number:	2846419	SOLUTROL	
Registration Number:	3349448	SUPERNUS	
Registration Number:	3336065	SUPERNUS PHARMACEUTICALS	
Registration Number:	3349449	SUPERNUS PHARMACEUTICALS	
Registration Number:	4498773	TROKENDI XR	
Registration Number:	4837107	YETARBA XR	
CORRESPONDENCE DATA			
Fax Number:	6102511408		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Phone:	610-251-5775		
Email:	trademarks@saul.com, Jen.Chungo@saul.com		
Correspondent Name:	SAUL EWING ARNSTEIN & LEHR LLP		
Address Line 1:	1200 Liberty Ridge Drive		
Address Line 2:	suite 200		
Address Line 4:	wayne, PENNSYLVANIA 19087-5569		

OP \$240.00 2410482

NAME OF SUBMITTER:	Gregory S. Bernabeo, reg. no. 44,032
SIGNATURE:	/Gregory S. Bernabeo/
DATE SIGNED:	11/30/2017
Total Attachments: 3 source=Term and Release - Trademarks#page1.tif source=Term and Release - Trademarks#page2.tif source=Term and Release - Trademarks#page3.tif	

TERMINATION AND RELEASE OF SECURITY INTEREST IN TRADEMARKS

This Termination and Release of Security Interest (the "**Release**") dated as of November 20, 2017, is made by **U.S. BANK NATIONAL ASSOCIATION**, in its capacity as collateral agent for the Secured Parties (in such capacity, together with its successors and assigns in such capacity, "**Collateral Agent**"). Capitalized terms used but not defined herein shall have the meaning assigned to such term in the Indenture (as defined below).

WITNESSETH:

WHEREAS, certain Convertible Senior Secured Notes were sold to Holders pursuant to certain transaction documents including but not limited to that certain Indenture, dated as of May 3, 2013, between Supernus Pharmaceuticals, Inc. (the "**Company**") and U.S. Bank National Association, as Trustee and Collateral Agent, as supplemented by the First Supplemental Indenture, dated as of October 24, 2013 (as so supplemented, the "**Indenture**"), and whereas that certain Trademark Security Agreement, dated as of May 3, 2013, by and among the Company and the Collateral Agent, was entered into to induce the Holders to purchase the Convertible Senior Secured Notes and granted to Collateral Agent a security interest in certain trademark registrations, trademark applications, trade names, common law trademarks and trademark licenses to secure the obligations of Company under the Indenture;


WHEREAS, as of August 3, 2017, the Company satisfied all of its obligations under the Convertible Senior Secured Notes and met its obligations to the Collateral Agent under the Indenture, which permitted the Company to terminate the Indenture and have all of its security released by the Collateral Agent including but not limited to the security under the Trademark Security Agreement; and

WHEREAS, pursuant to its covenant to assist the Company to have its Trademark Collateral (as that term is defined in the Trademark Security Agreement) released from any security obligation in connection with the Convertible Senior Secured Notes, the Collateral Agent hereby takes the following action to release the security interests provided for under the Trademark Security Agreement and/or the Indenture.

NOW THEREFORE, for good and valuable consideration, the Collateral Agent hereby terminates and releases its lien and security interest in the Trademark Collateral including, without limitation, the Trademark Collateral identified on Schedule 1 annexed hereto (the "**Released Collateral**"), and authorizes the U.S. Patent and Trademark Office and any other relevant parties, to modify their records to indicate the discharge of said lien and security interest.

IN WITNESS WHEREOF, this Termination and Release of Security Interest in Trademarks has been duly executed as of the day and year first above written by an authorized officer of the Collateral Agent.

U.S. BANK NATIONAL ASSOCIATION, as
Collateral Agent

By: 

Name: Alison D.B. Nadeau
Vice President


Title: _____

STATE OF Massachusetts)


)ss.:

COUNTY OF Suffolk)

On this 20 day of November 2017, before me the subscriber, personally appeared Alison D. B. Nadeau, who being by me duly sworn, did depose and say that she resides at 1 Federal Street, Boston, MA, that she is Vice President of U.S. BANK NATIONAL ASSOCIATION the entity described in and which executed the foregoing instrument; and that she signed her name thereto as Vice President of said entity.



NOTARY PUBLIC



SCHEDULE 1
to
TERMINATION AND RELEASE OF SECURITY INTEREST IN TRADEMARKS

Registrations

Owner	Registration Number	Country / State	Title
Supernus Pharmaceuticals, Inc.	2410482	USA	<u>MICROTROL</u>
Supernus Pharmaceuticals, Inc.	2505388	USA	<u>OPTISCREEN</u>
Supernus Pharmaceuticals, Inc.	4441262	USA	<u>OXTELLAR XR</u>
Supernus Pharmaceuticals, Inc.	2846419	USA	<u>SOLUTROL</u>
Supernus Pharmaceuticals, Inc.	3349448	USA	<u>SUPERNUS</u>
Supernus Pharmaceuticals, Inc.	3336065	USA	<u>SUPERNUS PHARMACEUTICALS</u>
Supernus Pharmaceuticals, Inc.	3349449	USA	<u>SUPERNUS PHARMACEUTICALS</u> (logo)
Supernus Pharmaceuticals, Inc.	4498773	USA	<u>TROKENDI XR</u>
Supernus Pharmaceuticals, Inc.	4837107	USA	<u>YETARBA XR</u>
Supernus Pharmaceuticals, Inc.	004575536	European Union	<u>SUPERNUS PHARMACEUTICALS</u>
Supernus Pharmaceuticals, Inc.	004575445	European Union	<u>SUPERNUS PHARMACEUTICALS</u> (logo)
Supernus Pharmaceuticals, Inc.	TMA736891	Canada	<u>SUPERNUS PHARMACEUTICALS</u>
Supernus Pharmaceuticals, Inc.	TMA737446	Canada	<u>SUPERNUS PHARMACEUTICALS</u> (logo)

Trademark Licenses

Trademarks	Name and Address of Licensee
Microtrol	Shire
Epliga, Trokendi XR, Oxtellar XR	Stendhal
Epliga, Trokendi XR, Oxtellar XR	Daewoong